Increase in people using weight loss drugs for Type 1 Diabetes treatment

GLP-1 Drugs for Type 1 Diabetes: Off-Label and Growing

FOX6 News Milwaukee covers a trend that's happening quietly in diabetes clinics across the country: people with type 1 diabetes are using GLP-1 drugs like Ozempic and Mounjaro, even though these medications are FDA-approved only for type 2 diabetes. The report is short and news-oriented, but it raises questions that deserve a deeper look.

First, the context. Type 1 diabetes is an autoimmune condition where the immune system destroys the insulin-producing beta cells in the pancreas. It's fundamentally different from type 2 diabetes, which is driven by insulin resistance and relative insulin insufficiency. GLP-1 drugs were designed and tested for type 2 diabetes, where they enhance existing insulin secretion and address metabolic dysfunction. In type 1 diabetes, the insulin-producing cells are gone or severely depleted, so the insulin-stimulating effect of GLP-1 drugs is limited or irrelevant.

So why are people with type 1 using them? The answer is multifaceted. First, many type 1 patients also develop insulin resistance over time, particularly if they gain weight. This combination is sometimes called "double diabetes" and it makes blood sugar management significantly harder. A GLP-1 drug can improve insulin sensitivity and reduce the total daily insulin dose needed, which makes blood sugar more stable and predictable.

The Benefits That Go Beyond Blood Sugar

Second, the appetite suppression and weight management effects matter. Type 1 diabetes treatment with insulin can cause weight gain, and that weight gain worsens insulin resistance, creating a frustrating cycle. GLP-1 drugs break this cycle by reducing appetite and promoting weight loss. Third, the slowed gastric emptying can help smooth out post-meal blood sugar spikes, which are one of the hardest things for type 1 patients to manage even with the best insulin regimens and continuous glucose monitors.

The news report interviews endocrinologists who are cautiously optimistic about this off-label use but emphasize the risks. The biggest concern is gastroparesis. Type 1 diabetes can cause diabetic gastroparesis (delayed stomach emptying from nerve damage), and adding a GLP-1 drug that further slows gastric emptying on top of pre-existing gastroparesis can cause severe nausea, vomiting, and dangerous blood sugar unpredictability. If you don't know when food is going to be absorbed, you don't know when to dose insulin, which creates a setup for both highs and lows.

There's also the hypoglycemia risk. While GLP-1 drugs themselves rarely cause hypoglycemia (because they only stimulate insulin when blood sugar is elevated), type 1 patients are on exogenous insulin, and the interaction between reduced food intake, slowed absorption, and insulin dosing can create hypoglycemic episodes that are hard to predict.

What the Report Gets Right

Acknowledging that this trend exists and is growing is important. Many patients are asking about or already using these drugs off-label, and pretending it's not happening doesn't serve anyone. The inclusion of endocrinologist perspectives adds clinical credibility to what could otherwise be a sensationalized story.

What's Missing

The report is thin on specifics. There are no clinical trial numbers, no discussion of which GLP-1 drug might be most appropriate for type 1 patients, and no mention of the research that is being done. There are actually several clinical trials underway specifically testing GLP-1 drugs in type 1 diabetes, and mentioning those would have added depth.

The safety discussion could also be more detailed. Beyond gastroparesis and hypoglycemia, there's the question of diabetic ketoacidosis (DKA). Some reports have linked SGLT2 inhibitor use in type 1 diabetes to increased DKA risk. While GLP-1 drugs have a different mechanism, the reduced food intake can theoretically increase ketone production in type 1 patients, and this risk needs to be monitored.

Questions for Your Endocrinologist

If you have type 1 diabetes and are curious about GLP-1 drugs:

Ask whether you have any features of insulin resistance that might make a GLP-1 drug worthwhile. If your total daily insulin dose is high relative to your body weight, or if your A1c is above target despite good carb counting, insulin resistance may be contributing. Ask about gastroparesis screening. Before adding a drug that slows gastric emptying, your doctor should evaluate whether your stomach emptying is already delayed.

Ask about CGM-based monitoring during the initiation period. If you start a GLP-1 drug, the changes in appetite and gastric emptying will affect your insulin dosing, and real-time glucose data is the safest way to adjust. Ask about ketone monitoring. Keeping ketone test strips (blood, not urine, for accuracy) available and knowing when to use them is a safety precaution that's especially relevant when food intake changes significantly. Ask whether any clinical trials for GLP-1 drugs in type 1 diabetes are enrolling near you.

The Insulin Interaction: Why Timing Matters More Than Usual

For type 1 patients using GLP-1 drugs, the interaction with insulin therapy creates unique challenges that don't exist in type 2 diabetes. Type 1 patients rely entirely on exogenous insulin, and they typically calculate their meal-time insulin doses based on the carbohydrate content of their food and their current blood sugar level. GLP-1 drugs disrupt both sides of this equation. The reduced appetite means patients eat less (and different) food, changing the carbohydrate input. The slowed gastric emptying changes the timing of carbohydrate absorption. And the reduced glucagon secretion means the liver releases less backup glucose during fasting periods.

The result is that insulin dosing algorithms developed for the pre-GLP-1 era may not work well. A type 1 patient who typically takes 6 units of rapid-acting insulin for a 60-gram carbohydrate meal may find that on a GLP-1 drug, they only eat 30 grams of carbs and the absorption is spread over a longer period. If they take their usual insulin-to-carb ratio dose, they may go low because the insulin peaks before the carbs are absorbed. Some endocrinologists recommend splitting the meal bolus into two smaller doses, or using the extended bolus feature on insulin pumps, to match the slower absorption profile. This kind of fine-tuning requires close collaboration between the patient and their diabetes team, and it's one reason why type 1 patients on GLP-1 drugs need more frequent follow-up than type 2 patients on the same medications.

The Research Space for Type 1 Diabetes and GLP-1 Drugs

While the off-label use of GLP-1 drugs in type 1 diabetes is growing, the formal research is still in relatively early stages. Several clinical trials are now specifically testing semaglutide and tirzepatide in type 1 diabetes populations, with primary endpoints focused on A1c improvement, total daily insulin dose reduction, and weight management. These trials are designed to address the unique safety concerns in type 1 diabetes, including gastroparesis risk, DKA risk, and hypoglycemia frequency. Preliminary results from some of these trials have been encouraging, showing meaningful reductions in total daily insulin requirements (typically 15-25%) and modest A1c improvements on top of existing insulin therapy.

The FDA has not approved any GLP-1 drug for type 1 diabetes, and this is unlikely to change until Phase 3 trial data is available. For patients considering off-label use, this regulatory status means insurance coverage is often denied, adding a financial barrier on top of the clinical considerations. Some patients are accessing these medications through prescriptions written for weight management rather than diabetes, which may be covered even in type 1 patients who have a BMI qualifying them for that indication. This workaround reflects the gap between clinical practice and regulatory approval that often exists when evidence is accumulating faster than the approval process can keep up.

Safety Red Lines That Must Not Be Crossed

For all the potential benefits, there are clear situations where GLP-1 drugs should not be used in type 1 diabetes patients. Anyone with a history of diabetic ketoacidosis in the past year should be extremely cautious, as the reduced food intake and metabolic changes could increase DKA risk. Patients with established gastroparesis (confirmed by gastric emptying study, more than symptoms) should generally avoid GLP-1 drugs because the additional gastric motility reduction can be dangerous. Patients who already experience significant hypoglycemia unawareness need to be on a reliable continuous glucose monitor before starting, and even then the risks need to be carefully weighed against the potential benefits.

The Psychological Dimension for Type 1 Patients

There's a psychological component to GLP-1 drug use in type 1 diabetes that rarely gets discussed. Many type 1 patients carry a complicated relationship with food and body weight. The requirement to count every carbohydrate, the weight gain associated with insulin therapy, and the constant mental math of diabetes management create a cognitive burden that can contribute to disordered eating patterns. Some type 1 patients restrict insulin to lose weight, a dangerous behavior sometimes called "diabulimia" that can lead to diabetic ketoacidosis and long-term complications.

The appetite suppression from GLP-1 drugs can be a double-edged sword in this context. For some patients, the reduced preoccupation with food is freeing, decreasing the mental energy spent on food-related decisions and allowing them to focus on other aspects of their lives. For others, particularly those with a history of restrictive eating, the dramatic appetite reduction could reinforce unhealthy patterns. Healthcare providers prescribing GLP-1 drugs to type 1 patients should screen for eating disorder history and monitor more than blood sugars but also eating patterns, psychological well-being, and nutritional adequacy throughout treatment.

Who Should Watch This

Type 1 diabetes patients who have heard about Ozempic or Mounjaro and wonder whether it could help them should watch this as a starting point. It won't give you all the answers, but it'll frame the right questions. Caregivers and parents of type 1 patients will also benefit from understanding the off-label space. Healthcare providers who treat type 1 diabetes should be aware that their patients are likely hearing about GLP-1 drugs from social media and news reports, and being prepared to discuss the risks and potential benefits proactively is better than finding out a patient has started the drug on their own.